Payer PolicyActive
CMM-204: Prolotherapy
EVICORE-MSK_ADVANCED-92316300
EviCore by Evernorth
Effective: August 1, 2022
Updated: January 13, 2026
created · Dec 5, 2025
Policy Summary
Prolotherapy (CPT M0076) for musculoskeletal pain and/or instability is designated experimental, investigational, or unproven and is not covered. The guideline cites inconclusive evidence and potential serious adverse effects, lists no covered indications or required documentation, and states atypical or unclear cases will require physician review/consultation.
Coverage Criteria Preview
Key requirements from the full policy
"Prolotherapy performed for the treatment of musculoskeletal pain and/or instability (e."
Sign up to see full coverage criteria, indications, and limitations.